Key takeaways
Triumeq (abacavir/dolutegravir/lamivudine) and Biktarvy (bictegravir/emtricitabine/tenofovir) are both single-tablet regimens used to treat HIV, but they have some key differences. Triumeq requires a genetic test before starting treatment to check for a specific trait that could cause a serious allergic reaction, while Biktarvy does not. Triumeq is available in two forms: a tablet for adults and children over 55 lbs, and a dissolvable tablet for children between 13 lbs and 54 lbs. Biktarvy, on the other hand, is only available as a tablet for those weighing at least 30 lbs. Both medications can cause liver problems and need to be taken with caution if you have severe liver or kidney issues. Both medications are also brand-only and can be expensive.
